Pluvicto availability - good news

[HopingForTheBest1]

Novartis has received FDA approval to begin supplying Pluvicto for US

commercial use from the Novartis Radioligand Therapy (RLT) manufacturing

facility in Millburn, New Jersey. This is an important step forward.

Production will begin in the coming weeks and gradually ramp up. The

site is expected to contribute meaningfully to supply in the third

quarter after the anticipated approval of additional lines. Capacity

should continue to increase through the second half of this year,

helping to ensure a stable, reliable supply to patients. The RLT

manufacturing facility in Ivrea, Italy, will continue to supply the US

market.

What this approval means for patients in the short term: 

Novartis is actively working with physicians in treatment centers administering Pluvicto to coordinate the scheduling of patient treatments.

With a gradual increase in new supply, Novartis expects to reduce the current issues that have led to treatment cancellations. Over time, patients who previously could not start on Pluvicto may be able to schedule a treatment with their healthcare providers.

What this means for Pluvicto supply in the long-term: 

The approval of the Millburn facility is a first step. Novartis says it will do it's best to deliver orders consistently while we scale up its RLT production capacity.

[Ahk1]

thanks very much for posting

[HopingForTheBest1]

Everyone should be seeing a post from Darryl, who originally sent this out earlier today as a blast email. Need to give credit where credit is due. Thanks Darryl.

[j-o-h-n]

Deposit bottles?

j-o-h-n <===<<< Senior management is about to spike my spikes....

Good Luck, Good Health and Good Humor.

j-o-h-n Saturday 04/22/2023 5:20 PM DST